Pneumocystis jirovecii pneumonia increases the 3-months mortality of anti-MDA5-antibody-positive dermatomyositis patients
PJP has high prevalence and mortality in anti-MDA5+DM, while TMP/SMZ prophylaxis significantly reduces PJP risk. Mortality in PJP+ patients is primarily concentrated within the first 3 months, associated with RPILD. Early intervention with corticosteroids and prophylactic measures are crucial in reducing mortality.
Authors
- Chenqiong Wang (ORCID: https://orcid.org/0000-0001-8450-6049)
- Zhaohui Zheng (ORCID: https://orcid.org/0000-0003-3817-0171)
- Zesong Li (ORCID: https://orcid.org/0000-0003-0975-4434)
- Gaohui Wei
- Zhaohui Su
- Congcong Gao (ORCID: https://orcid.org/0000-0003-1771-8847)
- Chunyi Zhang (ORCID: https://orcid.org/0000-0003-4544-7642)
- Ruxu Li
Institutions
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-28
- DOI
- https://doi.org/10.3389/fimmu.2024.1504380
- Citations
- 2
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- Henan Provincial Science and Technology Research Project